TaiMed Biologics Inc. AI Stock Analysis
TaiMed Biologics Inc. (4147) AI Stock Analysis
TaiMed Biologics Inc.
(TPEx:4147)
TaiMed Biologics scores below average, driven primarily by persistent unprofitability — flat revenue near NT$611 million, an operating loss of NT$194.6 million and negative return on equity — despite clear improvement in losses, margins and a first positive free-cash-flow year. A conservatively financed balance sheet with minimal leverage provides downside protection and runway. Technicals are a drag, with the price below all key moving averages and negative MACD momentum, while valuation provides no cushion given negative earnings and no dividend. The investment case rests on whether the recent margin and cash-flow gains prove sustainable enough to reach breakeven.
TaiMed Biologics Inc. (4147) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 16.54B
- Dividend Yield
- ―
- Average Volume (3M)
- 920.43K
- Price to Earnings (P/E)
- -103.7
- Beta (1Y)
- 0.31
- Revenue Growth
- 7.02%
- EPS Growth
- 25.72%
- Country
- TW
- Employees
- 799
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
TaiMed Biologics Inc. Business Overview & Revenue Model
Company Description
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. The company develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibod...
TaiMed Biologics Inc. Financial Statement Overview
Summary
A mixed but improving profile. The balance sheet is the standout strength: equity funds about 80% of assets and debt-to-equity is just 0.13, the lowest in years, giving this loss-making biotech genuine staying power. Cash flow marked an inflection, with operating cash flow swinging to a positive NT$191.1 million and free cash flow turning positive at NT$168.5 million after four years of burn. However, the income statement remains weak: revenue is flat at NT$611.4 million, and the company posted an operating loss of NT$194.6 million and a net loss of NT$167.8 million, with no profitable year on record. The positives are narrowing losses and gross margin recovery to 42.4%, but durability of the cash-flow turn and absence of profitability keep the profile speculative.
Income Statement
36NegativeBalance Sheet
70PositiveCash Flow
55Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 619.49M | 611.35M | 610.16M | 491.78M | 563.01M | 413.44M |
| Gross Profit | 283.54M | 259.45M | 211.22M | 225.23M | 215.71M | 83.95M |
| EBITDA | -17.44M | -41.66M | -35.57M | -24.61M | -102.74M | -306.83M |
| Net Income | -138.90M | -167.78M | -201.83M | -194.81M | -279.39M | -478.38M |
Balance Sheet | ||||||
| Total Assets | 4.50B | 4.81B | 5.00B | 3.89B | 4.10B | 4.61B |
| Cash, Cash Equivalents and Short-Term Investments | 1.61B | 1.77B | 1.65B | 649.13M | 645.40M | 960.89M |
| Total Debt | 478.14M | 493.12M | 522.63M | 750.86M | 766.14M | 567.32M |
| Total Liabilities | 824.49M | 953.05M | 976.34M | 1.33B | 1.39B | 1.67B |
| Stockholders Equity | 3.68B | 3.86B | 4.02B | 2.57B | 2.71B | 2.94B |
Cash Flow | ||||||
| Free Cash Flow | 107.91M | 168.47M | -398.90M | -31.75M | -609.97M | -224.84M |
| Operating Cash Flow | 155.12M | 191.14M | -379.55M | -25.60M | -605.21M | -211.28M |
| Investing Cash Flow | 288.45M | 154.02M | -714.84M | -16.45M | 106.11M | 190.92M |
| Financing Cash Flow | -164.53M | -21.64M | 1.41B | 19.23M | 208.38M | 2.79M |
TaiMed Biologics Inc. Peers Comparison
Overall Rating
TW:411461Neutral- TW:414747Neutral
TW:654740Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:4114 | 61Neutral | TWD 14.97B | 17.66 | ― | 3.06% | 11.40% | 9.36% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:4147 | 47Neutral | TWD 16.47B | -103.67 | ― | ― | 7.02% | 25.72% |
| TW:6547 | 40Underperform | TWD 16.94B | -409.93 | ― | ― | 44.37% | 78.11% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4147 | TaiMed Biologics Inc. | 61.90 | -5.30 | -7.89% | |
| TW:4114 | Synmosa Biopharma Corp | 27.75 | -1.98 | -6.67% | |
| TW:6547 | Medigen Vaccine Biologics Corp. | 46.35 | 9.30 | 25.10% | |
| TW:6586 | CHO Pharma, Inc. | 76.20 | 46.05 | 152.74% | |
| TW:6589 | EirGenix, Inc. | 51.70 | -22.80 | -30.60% | |
| TW:7871 | Elixiron Immunotherapeutics (Cayman) Limited | 114.50 | 75.00 | 189.87% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026